China is raising quality standards for pharmaceutical licensing following a string of deaths and injuries from faulty drugs, according to a state news agency. The new standard, which takes effect Jan. 1, will tighten rules that currently let a producer obtain a license if three “severe defects” are found but corrected, the Xinhua News Agency said Monday.
